Sandbox/v11: Difference between revisions
< Sandbox
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 14: | Line 14: | ||
* In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days. | * In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days. | ||
** The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment. | ** The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment. | ||
======Community-Acquired Meningitis====== | |||
{| | {| | ||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width: | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:30em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age <1 Week}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
Line 31: | Line 32: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ||
|- | |- | ||
Line 41: | Line 40: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}'' | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Tobramycin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—23 Months}}''<sup>†</sup> | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225—300 mg/kg/day IV q6–8h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 80—100 mg/kg/day IV q12–24h''''' | ||
|- | |||
|} | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:30em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 2—50 years}}<sup>†‡</sup>'' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | '' | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age >50 years}}'' | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h''''' | ||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised State}}'' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4 h''''' | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}'' | |||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | '' | |||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h''''' | ||
| | |} | ||
|} | |||
<SMALL><sup>†</sup>Add amoxicillin or ampicillin if meningitis caused by L monocytogenes is also suspected. Ampicillin if meningitis caused by L monocytogenes is also suspected </SMALL> | |||
<sup>‡</sup> fjljflkfdjklfjlsd |
Revision as of 18:39, 14 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Medical Therapy
Pharmacotherapy
Empiric Treatment
- Do not wait for the results of the CT scan and the lumbar puncture; empiric treatment should be started as soon as possible.
- Blood cultures should be drawn before starting the antibiotic therapy, and then the antibiotic treatment should be changed once the blood culture results are out.
- Empiric antibiotic treatment should be started within 30 minutes after the patient presentation.
- In case of high suspicion of pneumococcal meningitis in adult patients, 0.15 mg/kg IV Q6H dexomethasone should be administered for 2 to 4 days.
- The first dose of dexomethasone is given along with or 20 minutes prior to starting the antibiotics treatment.
Community-Acquired Meningitis
|
|
†Add amoxicillin or ampicillin if meningitis caused by L monocytogenes is also suspected. Ampicillin if meningitis caused by L monocytogenes is also suspected
‡ fjljflkfdjklfjlsd